Backgrounds/Aims: Metastasis in the pancreatic gland is infrequent, representing between 2-5% of the tumors that affect this organ. However, secondary lesions of clear cell renal carcinoma (CCRC) can occur mainly in this location and it is frequently the only site of dissemination. Treatment of choice is resection in surgically fit patients, as it has been shown that it improves the quality of life and prognosis substantially. We retrospectively reviewed the clinical data of patients with pancreatic resections for metastatic CCRC since there are no reports of the treatment modality of this singular entity in Argentina. Methods: Retrospective cohort analysis over a 10-year period including eight patients who underwent pancreatic resection for metastatic CCRC. Results: 75% of patients were male with an average age of 65.5 years. The pancreatic surgery occurred at a median time of 9.2 years (1-24.8) from the renal operation. The pancreatic lesions were mostly solitary and asymptomatic. A pancreaticoduodenectomy (PD) was performed in 4 patients (50%). Distal pancreatectomy (DP) was performed in 3 patients (37.3%) and one patient (12.5%) underwent a total pancreaticoduodenectomy. All the patients presented a confirmatory biopsy of pancreatic metastasis of CCRC. Complications were recorded in 3 patients (42.85%). No intraoperative or postoperative mortality was registered. With a median follow-up of 45 months, three patients presented recurrence at 32, 46 and 51 months, respectively. Only one patient showed death due to recurrence at 7.8 month. 
INTRODUCTION
One-third of patients operated with curative intentions will develop local or distant recurrence over time. 2 Although pancreatic metastases are usually rare, representing between 2 and 5% of the total of the neoplasms of the pancreas, this is an organ where CCRC secondary lesions mainly settle, and frequently as the only site of dissemination. They can appear in quite varying periods of time, with a range between 6 months and 7 years, being reported in the literature up to 32 years of the interval between nephrectomy and pancreatic metastases. 3 The diagnosis is usually made through imaging studies such as computed tomography (CT) and magnetic resonance imaging (MRI) during the oncological follow-up of the CCRC since they are typically asymptomatic. However, depending on the location and size, they can manifest clinically with abdominal pain, digestive bleeding, jaundice, pancreatitis and weight loss. 2, 4 The treatment of choice for the single pancreatic metastasis is the resection in surgically fit patients. They are technically resectable in 80% of cases and have shown to substantially improve the quality of life and prognosis of these patients. 5 There are some series of cases reported in the literature, A single patient clinically presented jaundice and multiple pancreatic metastatic nodules in imaging studies (Fig. 1 ).
In the rest of the patients, the pancreatic lesions were solitary, asymptomatic and detected during the follow-up of the underlying disease.
The indicated follow-up study of the CCRC, and with which diagnosis of pancreatic metastasis was made, was a multislice computed tomography scan with intravenous contrast. In one patient, scintigraphy with somatostatin analog radiolabeled with 111In (Indium) was requested due
to diagnostic doubt about a primitive neuroendocrine tumor of the pancreas. Biopsies of lesions were not performed preoperatively.
A pancreaticoduodenectomy (PD) was performed in 4 patients (50%) due to localized tumors in the head of the pancreas or in the uncinate process. Distal pancreatectomy (DP) was performed in 3 patients (37.3%) with tumors in the body and tail of the pancreas. One patient (12.5%) required total pancreaticoduodenectomy due to multiple pancreatic metastases. The approach of choice was the subcostal laparotomy in 7 patients (87.5%) and midline laparotomy in 1 patient (12.5%).
Of the 3 DPs, two were started laparoscopically and subsequently converted and concluded by conventional surgery, due to adhesions from previous renal surgery. All patients presented a confirmatory biopsy (by histology and immunohistochemistry) of pancreatic metastasis of CRCC (Fig. 2) . The size and number of metastatic nodules in the biopsy specimens are summarized in Table 1 .
One patient presented a posterior surgical margin of PD compromised by tumor (margin R1). In consequence, was treated with three-dimensional conformal radiation therapy delivered at 3 Grey / fraction up to 30 Grey in 10 fractions achieving stable local disease (no evidence of local recurrence). The rest of patients had free margins. The resected lymph nodes resulted in a 2-15 range. In all cases, the lymph nodes were negative for metastasis.
Complications were recorded in 3 patients (42.85%).
According to Dindo-Clavien (D-C) classification, 6 With a median follow-up of 45 months, three patients presented recurrence at 32, 46 and 51 months, respectively.
Only one patient showed death due to recurrence at 7.8 months ( Table 2) .
DISCUSSION
Metastases in the pancreas are infrequent, representing between 2% to 5% of tumors that affect this organ.
Neoplasms that most commonly affect it secondarily include CCRC, melanoma, colorectal, breast cancer and sarcomas. Pancreatic involvement of these entities usually indicates disseminated oncological disease. 7 Exception to the rule is the CCRC where a single metastases in the pancreas can exist in 50-73% of cases or multiple pancreatic metastases in 5-10% (in some series up to 45%) without affecting other organs. 8 Regarding the latter, in our series, two patients presented multiple nodules, one of them radiologically observed as a single nodule. But, as explained in the work of Zerbi et al. 4 such discordance can be found in up to 34.8% of patients.
Regarding presentation, according to the literature, we observed predominance in men (75%) with an average age of 65.5 years. 9 It has been suggested that dissemination could be lymphatically, owing to the anatomical proximity of the kidneys to the pancreas in the retroperitoneal space. 10 It is known that this study can be positive also in the metastatic CCRC but if it is not, the diagnosis of metastasis is favored. 14 In this case, the CCRC origin of the pancreatic nodule was confirmed in the histopathological study of the surgical specimen. Preoperative positron emission tomography has not been requested in any case due to its modest effectiveness, besides, it is not routinely recommended for CCRC staging. 12 No preoperative biopsy was performed in our series, although it would be useful to use biliopancreatic echoendoscopy or percutaneous biopsy depending on the case, in inoperable patients, in order to have a histological sample and therefore guide the specific oncological treatment.
Regarding surgical approach for CCRC pancreatic metastases, Bassi et al. 15 have shown a better survival and lower local recurrence with regulated resections, compared with atypical resections. Rückert et al. 16 recommend an even more aggressive approach, which includes not only standard pancreatic resections but also a routine lymphadenectomy, although there are no systematic studies to support it.
In our work, the selected resections were standard pan- However, the presence of lymphatic metastases has been reported as a factor of poor prognosis. 16 The complication rate was close to 40% in our study.
It could be explained by the fact that most pancreatectomies were PDs, and they required a pancreatic anastomosis in a soft consistency pancreas. That fact, in addition to the presence of a thin Wirsung duct in those patients, favors the development of a subsequent pancreatic fistula and other related complications. Some reports highlight the rate of complications and mortality as a determining factor to indicate surgery. 17 Fortunately, we did not register perioperative mortality in our series, and the complications registered in the current series were managed favorably. The mean hospital stay we recorded was 19 days, similar to that reported in the literature. 9 After pancreatic resection surgery, we considered a mean follow-up of 45 months of observation. In this period, 3 patients (37.5%) had a recurrence at 32 months (single bone metastasis); 46 months (in the pulmonary hilum) and at 51 months (multiple bone metastases). In all cases, medical treatment was instituted with tyrosine kinase inhibitors, thus achieving control of the disease. Only one patient presented death due to disseminated recurrence (cerebral, bone and pulmonary) at 7.8 months, probably carrying a highly aggressive tumor biology. 10 Currently, 50% of patients who underwent a pancreatic metastasis of CCRC resection in these series are alive and free of disease. Patients who had an extra-pancreatic recurrence after surgery had a minimum interval of 32 months free-disease survival. In any case, they have remained with stable disease at 45-month follow-up average. This trend is comparable to the study by Schwarz et al. 18 that has the longest follow-up in the treatment of this disease, where they have reported a global survival at 3-, 5-, and 10 years of 72, 63, and 32%, respectively.
In conclusion, CCRC pancreatic metastases are infrequent, they usually do not present symptoms and appear after prolonged intervals of time after renal surgery, consequently demanding a lifetime follow-up. These, treated surgically in selected patients, have a low morbidity and mortality rates in high volume centers and have excellent results regarding long-term survival.
